3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
13
Breast Neoplasms
11
Carcinoma, Transitional Cell
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
3
Small Cell Lung Carcinoma
2
Urothelial Bladder Carcinoma
1
Salivary Gland Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Liver Failure
1
HRD Cancer
1
Glioblastoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma, Small Cell
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Paclitaxel
10
Carboplatin
6
Bevacizumab
5
liposomal doxorubicin
4
Topotecan
3
Cyclophosphamide
3
pembrolizumab
2
oregovomab
2
olaparib
2
niraparib
2
fludarabine
2
Nivolumab
2
Drug Therapy
2
trastuzumab deruxtecan
1
rucaparib
1
ribociclib
1
palbociclib
1
mirvetuximab soravtansine
1
isoquercitrin
1
irinotecan sucrosofate
1
fludarabine phosphate
1
denileukin diftitox
1
anlotinib
1
Tinzaparin
1
Saline Solution
1
Propranolol
1
Preoperative Exercise
1
Platinum
1
Palliative Care
1
Neoadjuvant Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
sacituzumab govitecan
×
90 days
×
Clear all
No trials found.